NASDAQ:LNTH

Lantheus Stock Forecast, Price & News

$21.70
-0.10 (-0.46 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.52
Now: $21.70
$21.97
50-Day Range
$18.31
MA: $20.03
$21.80
52-Week Range
$10.52
Now: $21.70
$21.99
Volume393,153 shs
Average Volume558,801 shs
Market Capitalization$1.45 billion
P/E Ratio271.28
Dividend YieldN/A
Beta1.32
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Lantheus logo

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LNTH
CUSIPN/A
Phone978-671-8001
Employees595
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$347.34 million
Cash Flow$2.16 per share
Book Value$2.92 per share

Profitability

Net Income$31.67 million

Miscellaneous

Market Cap$1.45 billion
Next Earnings Date4/29/2021 (Estimated)
OptionableOptionable

Headlines

Lantheus Target of Unusually High Options Trading (NASDAQ:LNTH)
April 16, 2021 |  americanbankingnews.com
Lantheus (NASDAQ:LNTH) Shares Up 4.1%
March 30, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.48 out of 5 stars

Medical Sector

553rd out of 2,024 stocks

Diagnostic Substances Industry

8th out of 32 stocks

Analyst Opinion: 1.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$21.70
-0.10 (-0.46 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LNTH News and Ratings via Email

Sign-up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Lantheus (NASDAQ:LNTH) Frequently Asked Questions

Is Lantheus a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Lantheus stock.
View analyst ratings for Lantheus
or view top-rated stocks.

What stocks does MarketBeat like better than Lantheus?

Wall Street analysts have given Lantheus a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lantheus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Lantheus' next earnings date?

Lantheus is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Lantheus
.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) issued its quarterly earnings results on Thursday, February, 25th. The medical equipment provider reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.04. The medical equipment provider earned $94.15 million during the quarter, compared to analyst estimates of $94.40 million. Lantheus had a trailing twelve-month return on equity of 11.05% and a net margin of 0.12%.
View Lantheus' earnings history
.

How has Lantheus' stock price been impacted by Coronavirus (COVID-19)?

Lantheus' stock was trading at $13.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, LNTH shares have increased by 59.3% and is now trading at $21.70.
View which stocks have been most impacted by COVID-19
.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus issued an update on its FY21 earnings guidance on Thursday, February, 25th. The company provided earnings per share guidance of $0.34-0.39 for the period, compared to the Thomson Reuters consensus estimate of $0.42. The company issued revenue guidance of $385-400 million, compared to the consensus revenue estimate of $408.33 million.

What price target have analysts set for LNTH?

4 brokers have issued 12 month price objectives for Lantheus' stock. Their forecasts range from $17.00 to $29.00. On average, they anticipate Lantheus' share price to reach $23.67 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price.
View analysts' price targets for Lantheus
or view top-rated stocks among Wall Street analysts.

Who are Lantheus' key executives?

Lantheus' management team includes the following people:
  • Ms. Mary Anne Heino, CEO, Pres & Director (Age 61, Pay $1.53M)
  • Mr. Robert J. Marshall Jr., CFO & Treasurer (Age 54, Pay $804.4k)
  • Mr. John J. Bolla, Chief Operating Officer (Age 51, Pay $533.86k)
  • Mr. Michael P. Duffy, Sr. VP of Law & Public Policy and Gen. Counsel (Age 60, Pay $662.61k)
  • Mr. Mark Richard Kinarney, Sr. Director of Investor Relations
  • Ms. Meara Murphy, Director of Corp. Communications
  • Mr. Etienne Montagut, Sr. VP of Corp. Devel. (Age 46)
  • Ms. Carol Walker, Sr. VP of Quality (Age 58)
  • Dr. Istvan Molnar M.D., Chief Medical Officer (Age 54)
  • Mr. Paul Blanchfield, Chief Commercial Officer (Age 40)

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus CEO Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among Lantheus' employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Lantheus' key competitors?

What other stocks do shareholders of Lantheus own?

When did Lantheus IPO?

(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a variety of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.07%). Company insiders that own Lantheus stock include Brian A Markison, Cesare Orlandi, Derace L Schaffer, Heinz Christoph Maeusli, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall, Sam R Leno and Tudor Brown.
View institutional ownership trends for Lantheus
.

Which major investors are selling Lantheus stock?

LNTH stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Lantheus company stock in the last year include John J Bolla, Mary Anne Heino, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall, and Sam R Leno.
View insider buying and selling activity for Lantheus
or view top insider-selling stocks.

How do I buy shares of Lantheus?

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $21.70.

How much money does Lantheus make?

Lantheus has a market capitalization of $1.45 billion and generates $347.34 million in revenue each year. The medical equipment provider earns $31.67 million in net income (profit) each year or $1.17 on an earnings per share basis.

How many employees does Lantheus have?

Lantheus employs 595 workers across the globe.

What is Lantheus' official website?

The official website for Lantheus is www.lantheus.com.

Where are Lantheus' headquarters?

Lantheus is headquartered at 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.